ATLANTA, Nov. 14, 2024 (GLOBE NEWSWIRE) — Holzer & Holzer, LLC reminds investors of the November 25, 2024 Lead Plaintiff deadline in the following class action lawsuits.
Bumble Inc.
A shareholder class action lawsuit has been filed against Bumble Inc. (“Bumble” or the “Company”) (NASDAQ: BMBL). The lawsuit alleges that Defendants created the false impression that they possessed reliable information pertaining to the Company’s projected revenue outlook and anticipated growth, while also downplaying the potential disruption to Bumble’s brand and reputation caused by the imminent change in leadership. Such statements are alleged to have caused Plaintiff and other shareholders to purchase Bumble’s securities at artificially inflated prices.
If you bought shares of Bumble between November 7, 2023 and August 7, 2024, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at http://holzerlaw.com/case/bumble/ to learn more.
Metagenomi, Inc.
A shareholder class action lawsuit has been filed against Metagenomi, Inc. (“Metagenomi” or “the Company”) (NASDAQ: MGX). The lawsuit alleges that Defendants made materially false and misleading statements and/or failed to disclose material adverse information in Metagenomi’s Registration Statement concerning the Company’s collaboration agreement with Moderna, resulting in harm to investors.
If you bought shares of Metagenomi on or after the Company’s February 13, 2024 IPO, and you suffered a significant loss on that investment, you are encouraged to discuss your legal rights by contacting Corey D. Holzer, Esq. at cholzer@holzerlaw.com, by toll-free telephone at (888) 508-6832 or you may visit the firm’s website at www.holzerlaw.com/case/metagenomi/ to learn more.
Holzer & Holzer, LLC, an ISS top rated securities litigation law firm for 2021, 2022, and 2023, dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. Since its founding in 2000, Holzer & Holzer attorneys have played critical roles in recovering hundreds of millions of dollars for shareholders victimized by fraud and other corporate misconduct. More information about the firm is available through its website, https://holzerlaw.com/, and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey Holzer is the attorney responsible for its content.
CONTACT:
Corey Holzer, Esq.
(888) 508-6832 (toll-free)
cholzer@holzerlaw.com
- TECVAYLI®▼ (teclistamab) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma - December 8, 2024
- Longer-term data for Novartis Scemblix® reinforce superior efficacy with favorable safety and tolerability profile in adults with newly diagnosed CML - December 8, 2024
- Five-year results confirm Roche’s Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma - December 8, 2024